Aardvark Therapeutics

#Prader-Willi Syndrome #Hyperphagia #Obesity and Metabolic Disease #Bitter Taste Receptor (TAS2R) Biology #Inflammation

Aardvark Therapeutics is a clinical-stage biopharmaceutical company developing small-molecule therapeutics that activate innate homeostatic pathways — including bitter taste receptors (TAS2R) — to treat metabolic and inflammatory disease. Its lead candidate ARD-101 targets hyperphagia in Prader-Willi syndrome; the Phase 3 HERO trial was voluntarily paused in February 2026 and terminated, and the FDA lifted its clinical hold in October 2026, leaving the programme awaiting a redesigned Phase 3 and a lower-dose resumption. A second programme, ARD-201, is in development for obesity.

Company Info

Sector:Biotechnology / Metabolic Disease

Headquarters:San Diego, California, USA

Founded:2017

Website:aardvarktherapeutics.com/

Upcoming Milestones & Key Dates

2027

Regulatory

FDA meeting on a new Phase 3 design and lower-dose ARD-101 resumption; PWS clinical activity expected to restart

Clinical Development Pipeline

ARD-101

Target: Gut-expressed bitter taste receptors (TAS2R)

Hyperphagia associated with Prader-Willi syndrome

Preclinical

Phase 1

Phase 2

Phase 3

Approved

ARD-201

Target: Bitter taste receptor pathway

Obesity and metabolic disease

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Leadership Team

Tien-Li Lee, M.D.

Chief Executive Officer, Chairman and Secretary

Nelson B. Sun, M.B.A.

Chief Financial Officer and Chief Operating Officer

Manasi Sinha Jaiman, M.D., M.P.H.

Chief Medical Officer

Careers & Job Openings

No active job listings. Check back later.